MA33091B1 - Combinaisons pharmaceutiques comprenant rdea119/bay 869766 pour le traitement de cancers specifiques - Google Patents

Combinaisons pharmaceutiques comprenant rdea119/bay 869766 pour le traitement de cancers specifiques

Info

Publication number
MA33091B1
MA33091B1 MA34134A MA34134A MA33091B1 MA 33091 B1 MA33091 B1 MA 33091B1 MA 34134 A MA34134 A MA 34134A MA 34134 A MA34134 A MA 34134A MA 33091 B1 MA33091 B1 MA 33091B1
Authority
MA
Morocco
Prior art keywords
cancer
rdea119
bay
treatment
specific cancer
Prior art date
Application number
MA34134A
Other languages
English (en)
Inventor
Mark S Chapman
Original Assignee
Ardea Biosciences Inc
Cabinet Patentmark
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42135921&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA33091(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ardea Biosciences Inc, Cabinet Patentmark filed Critical Ardea Biosciences Inc
Publication of MA33091B1 publication Critical patent/MA33091B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pathology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

LA PRÉSENTE INVENTION CONCERNE LE DOMAINE DE L'ONCOLOGIE ET PROPOSE DES COMPOSITIONS ET DES PROCÉDÉS POUR TRAITER DES CANCERS SPÉCIFIQUES, COMPRENANT UN CANCER DU POUMON NON À PETITES CELLULES, UN CANCER DU SEIN, UN CANCER DE LA THYROÏDE, UN CANCER DU PANCRÉAS, UN CANCER DU CÔLON, UN MÉLANOME, UN HÉPATOME ET UN ADÉNOCARCINOME.
MA34134A 2009-03-11 2010-03-11 Combinaisons pharmaceutiques comprenant rdea119/bay 869766 pour le traitement de cancers specifiques MA33091B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15940309P 2009-03-11 2009-03-11
PCT/US2010/027060 WO2010105110A1 (fr) 2009-03-11 2010-03-11 Combinaisons pharmaceutiques comprenant rdea119/bay 869766 pour le traitement de cancers spécifiques

Publications (1)

Publication Number Publication Date
MA33091B1 true MA33091B1 (fr) 2012-03-01

Family

ID=42135921

Family Applications (1)

Application Number Title Priority Date Filing Date
MA34134A MA33091B1 (fr) 2009-03-11 2010-03-11 Combinaisons pharmaceutiques comprenant rdea119/bay 869766 pour le traitement de cancers specifiques

Country Status (23)

Country Link
US (2) US8673876B2 (fr)
EP (1) EP2405908B1 (fr)
JP (2) JP5767122B2 (fr)
KR (1) KR20110132371A (fr)
CN (2) CN102421427B (fr)
AU (1) AU2010224044A1 (fr)
BR (1) BRPI1009448A2 (fr)
CA (2) CA2972379A1 (fr)
CL (1) CL2011002233A1 (fr)
CO (1) CO6430423A2 (fr)
CR (1) CR20110479A (fr)
CU (1) CU20110170A7 (fr)
DO (1) DOP2011000282A (fr)
EA (1) EA201101302A1 (fr)
EC (1) ECSP11011314A (fr)
HK (1) HK1199710A1 (fr)
IL (1) IL214749A0 (fr)
MA (1) MA33091B1 (fr)
MX (1) MX2011009498A (fr)
PE (1) PE20120105A1 (fr)
SG (1) SG174272A1 (fr)
TN (1) TN2011000455A1 (fr)
WO (1) WO2010105110A1 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7723477B2 (en) 2005-10-31 2010-05-25 Oncomed Pharmaceuticals, Inc. Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth
EP2331136B1 (fr) 2008-09-26 2018-01-10 OncoMed Pharmaceuticals, Inc. Agents se liant aux récepteurs frizzled et leurs utilisations
TWI535445B (zh) 2010-01-12 2016-06-01 安可美德藥物股份有限公司 Ｗｎｔ拮抗劑及治療和篩選方法
WO2013001372A2 (fr) * 2011-06-30 2013-01-03 University Of Oslo Procédés et compositions pour inhiber l'activation des lymphocytes t régulateurs
WO2013086260A2 (fr) * 2011-12-09 2013-06-13 Oncomed Pharmaceuticals, Inc. Thérapie d'association pour le traitement du cancer
WO2014071183A1 (fr) 2012-11-02 2014-05-08 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Méthode de réduction des effets secondaires chez un patient souffrant de cancer traité par un inhibiteur de la mek
CN105073195A (zh) 2013-02-04 2015-11-18 昂科梅德制药有限公司 使用Wnt途径抑制剂进行治疗的方法及对该治疗的监测
EP2848246A1 (fr) * 2013-09-13 2015-03-18 Bayer Pharma Aktiengesellschaft Compositions pharmaceutiques contenant du refametinib
EP3043778B1 (fr) * 2013-09-13 2017-09-06 Bayer Pharma Aktiengesellschaft Compositions pharmaceutiques contenant du refametinib
US20170114323A1 (en) 2014-06-19 2017-04-27 Whitehead Institute For Biomedical Research Uses of kinase inhibitors for inducing and maintaining pluripotency
US12371667B2 (en) 2021-05-13 2025-07-29 Washington University Enhanced methods for inducing and maintaining naive human pluripotent stem cells

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9925958D0 (en) * 1999-11-02 1999-12-29 Bundred Nigel J Therapeutic use
AU2002234165A1 (en) * 2000-11-03 2002-05-27 Tularik, Inc. Combination therapy using pentafluorobenzenesulfonamides and antineoplastic agents
JP2005531488A (ja) * 2001-10-09 2005-10-20 ザ・ユニバーシティ・オブ・シンシナティ 甲状腺癌を処置するためのｅｇｆ受容体阻害剤
EP1620109A2 (fr) 2003-04-25 2006-02-01 Gilead Sciences, Inc. Analogues de phosphonate inhibiteurs de kinase
US20080306097A1 (en) * 2004-12-17 2008-12-11 Smithkline Beecham (Cork) Limited Cancer Treatment Method
WO2006076463A2 (fr) * 2005-01-12 2006-07-20 Amgen Inc. Sondes fondees sur l'activite ciblant les kinases
JP5106098B2 (ja) * 2005-02-28 2012-12-26 エーザイ・アール・アンド・ディー・マネジメント株式会社 スルホンアミド化合物の抗癌剤との新規併用
US8101799B2 (en) * 2005-07-21 2012-01-24 Ardea Biosciences Derivatives of N-(arylamino) sulfonamides as inhibitors of MEK
MX2008002114A (es) 2005-07-21 2008-04-17 Ardea Biosciences Inc Inhibidores de n-(arilamino)-sulfonamida de mek.
US20090017050A1 (en) 2007-07-13 2009-01-15 Ventana Medical Systems, Inc. Egfr antigen-binding molecules and uses thereof
CA2694646C (fr) * 2007-07-30 2017-09-05 Ardea Biosciences, Inc. Combinaisons d'inhibiteurs de mek et d'inhibiteurs de raf kinase et leurs utilisations
CN103479604B (zh) * 2007-07-30 2016-08-10 阿迪生物科学公司 作为mek抑制剂的包括多晶型物的n-(芳氨基)磺酰胺衍生物和组合物、其使用方法和制备方法
US8044240B2 (en) * 2008-03-06 2011-10-25 Ardea Biosciences Inc. Polymorphic form of N-(S)-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide and uses thereof
DE102008031039A1 (de) * 2008-06-30 2009-12-31 Dömling, Alexander, Priv.-Doz. Dr. Tarceva zur Anwendung in der Organtransplantation.

Also Published As

Publication number Publication date
CN102421427A (zh) 2012-04-18
MX2011009498A (es) 2011-10-14
KR20110132371A (ko) 2011-12-07
CO6430423A2 (es) 2012-04-30
CN103948600A (zh) 2014-07-30
JP5911929B2 (ja) 2016-04-27
US8673876B2 (en) 2014-03-18
JP5767122B2 (ja) 2015-08-19
DOP2011000282A (es) 2011-10-15
SG174272A1 (en) 2011-10-28
JP2012520321A (ja) 2012-09-06
JP2014237716A (ja) 2014-12-18
AU2010224044A1 (en) 2011-09-22
EA201101302A1 (ru) 2012-05-30
CA2754913C (fr) 2017-08-22
US9220696B2 (en) 2015-12-29
CL2011002233A1 (es) 2012-02-03
PE20120105A1 (es) 2012-02-22
BRPI1009448A2 (pt) 2016-03-01
CU20110170A7 (es) 2012-06-21
TN2011000455A1 (en) 2013-03-27
CR20110479A (es) 2011-10-24
US20140080783A1 (en) 2014-03-20
ECSP11011314A (es) 2011-10-31
EP2405908B1 (fr) 2016-12-21
HK1199710A1 (en) 2015-07-17
CN102421427B (zh) 2013-11-06
US20120071435A1 (en) 2012-03-22
CA2972379A1 (fr) 2010-09-16
HK1169603A1 (en) 2013-02-01
WO2010105110A1 (fr) 2010-09-16
CA2754913A1 (fr) 2010-09-16
IL214749A0 (en) 2011-11-30
EP2405908A1 (fr) 2012-01-18

Similar Documents

Publication Publication Date Title
AU2017225061B2 (en) Biomarkers and methods of treating PD-1 and PD-L1 related conditions
CR20110479A (es) Combinaciones farmaceuticas que comprenden rdea 119/bay 869766 para el tratamiento de canceres especificos
MX2018010261A (es) Inhibidores de idh1 para el tratamiento de neoplasias malignas hematologicas y tumores solidos.
EP1844077A4 (fr) Anticorps dr5 et utilisations de ceux-ci
CL2018000955A1 (es) Terapia de combinación para el tratamiento de neoplasias malignas
EA201201400A1 (ru) Композиции и способы лечения аутоиммунных и других заболеваний
WO2007016548A3 (fr) Procedes et compositions a base de micro-arn pour le diagnostic, le pronostic et le traitement du cancer du sein
WO2007081680A3 (fr) Anomalies dans l'expression des micro-arn dans des tumeurs endocrines pancréatiques et des tumeurs à cellules acineuses
MA33469B1 (fr) Polythérapie à base d'un anticorps afucosylé anti-cd20 et de bendamustine
TR200906131T1 (tr) Aktivin -actrIIa antagonistleri ve göğüs kanserinin tedavi e
WO2007033023A3 (fr) Compositions et methodes pour le diagnostic et le traitement de cancers associes au gene bcl2
EA201890957A1 (ru) Комбинированная терапия для лечения злокачественных опухолей
WO2007062138A3 (fr) Procedes et compositions pour le traitement de maladies ciblant la prominin-1(cd133) humaine
WO2013192423A3 (fr) Méthodes et compositions utiles pour traiter les maladies impliquant des protéines de la famille bcl-2 avec des dérivés de quinoline
MX336761B (es) Compuestos para el tratamiento de cancer.
WO2008115750A3 (fr) Compositions et procédés pour le traitement du cancer
NZ603952A (en) Phosphaplatins and their use for treatment of cancers
PH12018500003A1 (en) Treatment of patients diagnosed with pancreatic ductal adenocarcinoma
MX2009010271A (es) Tratamiento combinado del cancer con anticuerpo anti cd20 e interleucina 18 humana.
FR2945210B1 (fr) Combinaison antitumorale comprenant l'ave8062 et le sorafenib
EP4286853A3 (fr) Compositions présentant une grande spécificité pour l'évaluation du cancer de l'ovaire
WO2013081645A3 (fr) Mutations dans erbb3 dans des cancers
MX2012012479A (es) Metodos, composiciones y accesorios para proporcionar un tratamiento terapeutico.
EP2099458A4 (fr) Composés et procédés pour imagerie et thérapie de tumeurs médiées par des enzymes
MX2017009857A (es) Isoformas delta133p53beta y delta133p53gamma son biomarcadores de celulas madre cancerosas.